MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202621109944 A) filed by Chetan Y. Kadam; and Dr. Namrata Singh on September 14, 2026, for Formulation And In Vitro Evaluation Of Intranasal Medicated Gel For Enhanced Delivery In Alzheimer’s Disease.
Inventors include Chetan Y. Kadam; and Dr. Namrata Singh.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and neuronal loss. Conventional oral therapies often exhibit limited therapeutic efficacy due to poor blood–brain barrier permeability, extensive first-pass metabolism, and systemic adverse effects. Intranasal drug delivery has emerged as a promising non-invasive approach for direct nose-to-brain transport, enabling rapid drug absorption and enhanced bioavailability in the central nervous system. The present study aimed to formulate and evaluate an intranasal medicated gel for improved drug delivery in the management of Alzheimer’s disease. The gel formulations were prepared using suitable mucoadhesive polymers and evaluated for physicochemical properties including appearance, pH, viscosity, gel strength, drug content uniformity, spreadability, and mucoadhesive strength. In vitro drug release studies were performed using diffusion techniques to assess the release behavior of the incorporated drug. The developed formulations exhibited satisfactory physicochemical characteristics, acceptable nasal compatibility, and sustained drug release profiles. Enhanced mucoadhesion and prolonged nasal residence time were observed, indicating the potential of the gel system to improve drug absorption through the nasal mucosa. The findings suggest that the formulated intranasal medicated gel may serve as an effective and patient-friendly platform for targeted brain delivery, offering a promising therapeutic strategy for the treatment of Alzheimer’s disease. Further in vivo investigations are warranted to confirm its brain-targeting efficiency and therapeutic effectiveness.
Disclaimer: Curated by HT Syndication.
